Beta Bionics, Inc., a company at the forefront of medical device innovation, is gearing up for its...
3 new filings this week
Flowco Holdings Inc., a leader in oil and gas production optimization and methane abatement, is going public on the NYSE under "FLOC." With innovative solutions, a unique UP-C structure, and cornerstone backing from BlackRock, the IPO promises stability and growth in a critical energy sector
Beta Bionics, Inc. is going public on Nasdaq under "BBNX" with its groundbreaking iLet Bionic Pancreas, an FDA-cleared device that simplifies diabetes management using adaptive algorithms. With proven clinical success and plans for expansion into type 2 diabetes and next-gen devices, the company aims to revolutionize diabetes care.
Maze Therapeutics, going public on Nasdaq as "MAZE," is pioneering precision medicine for chronic kidney disease (CKD) using its Compass platform. Its lead programs target genetic drivers of CKD, aiming to transform care for patients with unmet needs.